![](https://investorshub.advfn.com/uicon/58273.png?cb=1498574468)
Monday, June 15, 2020 7:55:54 PM
LOS ANGELES, June 15, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Co-Diagnostics, Inc. (NASDAQ: CODX) investors that the firm has initiated an investigation into alleged violations of securities laws, and may file a lawsuit on behalf of investors to recover losses suffered by investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, including eligibility for appointment as a class representative.
The investigation focuses on whether Co-Diagnostics, Inc. through its officers misled investors regarding the reliability and accuracy of the company’s testing for COVID-19. Specifically, the investigation focuses on whether the company’s statements that its tests were 100% accurate in fact misled investors and improperly inflated the price of the stock.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors from around the world and specializes in securities class actions and shareholder rights litigation. Attorney advertising. Prior results do not guarantee similar outcomes.
Opti
Hebrews 11:6 And without faith it is impossible to please Him, for he who comes to God must believe that He is and that He is a rewarder of those who seek Him.
Recent CODX News
- Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21 • PR Newswire (US) • 06/18/2024 05:30:00 PM
- Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform • PR Newswire (US) • 06/14/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:35:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 08:01:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 08:01:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:01:37 PM
- Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:01:00 PM
- Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast • PR Newswire (US) • 04/25/2024 01:30:00 PM
- Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan • PR Newswire (US) • 04/24/2024 01:30:00 PM
- Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event • PR Newswire (US) • 04/12/2024 01:30:00 PM
- Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions • PR Newswire (US) • 04/04/2024 01:30:00 PM
- Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address • PR Newswire (US) • 03/21/2024 01:30:00 PM
- Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England • PR Newswire (US) • 03/18/2024 01:30:00 PM
- Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results • PR Newswire (US) • 03/14/2024 08:01:00 PM
- Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test • PR Newswire (US) • 03/07/2024 02:30:00 PM
- Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast • PR Newswire (US) • 02/29/2024 02:30:00 PM
- Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024 • PR Newswire (US) • 02/01/2024 02:30:00 PM
- Co-Diagnostics, Inc. to Host Booth at CES 2024 January 9-12 • PR Newswire (US) • 01/03/2024 02:30:00 PM
- Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro • PR Newswire (US) • 12/27/2023 02:30:00 PM
- Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023 • PR Newswire (US) • 11/29/2023 02:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 09:50:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 09:38:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 09:37:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:05:45 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM